Antiretroviral agents increase NO production in gp120/IFNγ-stimulated cultures of rat microglia via an arginase-dependent mechanism

Journal of Neuroimmunology

Volumn 266, Issue 1-2, 2014, Pages 24-32

  Lisi, Lucia ^a   Tramutola, Antonella ^a   Navarra, Pierluigi ^a   Dello Russo, Cinzia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antiretroviral drugs; Arginase; HIV; Microglia; NO; Urea

Indexed keywords

ANTIVIRUS AGENT; ARGINASE 1; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; GAMMA INTERFERON; GLYCOPROTEIN GP 120; INDUCIBLE NITRIC OXIDE SYNTHASE; NEVIRAPINE; NITRIC OXIDE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84891482258     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.10.013     Document Type: Article

References (34)

1. Bogdan C., Röllinghoff M., Diefenbach A. The role of nitric oxide in innate immunity. Immunol. Rev. 2000, 173:17-26.
2. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 2005, 5:641-654.
3. Clifford D.B. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008, 16:94-98.
4. Cloke T.E., Abebe T., Hailu A., Munder M., Taylor G.P., Müller I., Kropf P. Antiretroviral therapy abrogates association between arginase activity and HIV disease severity. Trans. R. Soc. Trop. Med. Hyg. 2010, 104:746-748.
5. Cloke T.E., Garvey L., Choi B.S., Abebe T., Hailu A., Hancock M., Kadolsky U., Bangham C.R., Munder M., Müller I., Taylor G.P., Kropf P. Increased level of arginase activity correlates with disease severity in HIV-seropositive patients. J. Infect. Dis. 2010, 202:374-385.
6. Cysique L.A., Brew B.J. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol. Rev. 2009, 19:169-185.
7. Cysique L.A., Waters E.K., Brew B.J. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications foruture research. BMC Neurol. 2011, 11:148.
8. De Simone R., Vissicchio F., Mingarelli C., De Nuccio C., Visentin S., Ajmone-Cat M.A., Minghetti L. Branched-chain amino acids influence the immune properties of microglial cells and their responsiveness to pro-inflammatory signals. Biochim. Biophys. Acta 2013, 1832:650-659.
9. Dello Russo C., Boullerne A.I., Gavrilyuk V., Feinstein D.L. Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflammation 2004, 1:9.
10. Dello Russo C., Lisi L., Tringali G., Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem. Pharmacol. 2009, 78:1242-1251.
11. Grovit-Ferbas K., Harris-White M.E. Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction. Immunol. Res. 2010, 48:40-58.
12. Joska J.A., Gouse H., Paul R.H., Stein D.J., Flisher A.J. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J. Neurovirol. 2010, 16:101-114.
13. Kropf P., Fuentes J.M., Fähnrich E., Arpa L., Herath S., Weber V., Soler G., Celada A., Modolell M., Müller I. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 2005, 19:1000-1002.
14. Lagathu C., Eustace B., Prot M., Frantz D., Gu Y., Bastard J.P., Maachi M., Azoulay S., Briggs M., Caron M., Capeau J. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir. Ther. 2007, 12:489-500.
15. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5:227-231.
16. Letendre S., Marquie-Beck J., Capparelli E., Best B., Clifford D., Collier A.C., Gelman B.B., McArthur J.C., McCutchan J.A., Morgello S., Simpson D., Grant I., Ellis R.J., CHARTER Group Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008, 65:65-70.
17. Liner K.J., Ro M.J., Robertson K.R. HIV, antiretroviral therapies, and the brain. Curr. HIV/AIDS Rep. 2010, 7:85-91.
18. Lisi L., Tramutola A., De Luca A., Navarra P., Dello Russo C. Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120. J. Neurochem. 2012, 120:106-114.
19. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
20. Marra C.M., Zhao Y., Clifford D.B., Letendre S., Evans S., Henry K., Ellis R.J., Rodriguez B., Coombs R.W., Schifitto G., McArthur J.C., Robertson K., AIDS Clinical Trials Group 736 Study Team Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009, 23:1359-1366.
21. May M.T., Ingle S.M. Life expectancy of HIV-positive adults: a review. Sex. Health 2011, 8:526-533.
22. Mori M. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 2007, 137:1616S-1620S.
23. Munder M., Eichmann K., Morán J.M., Centeno F., Soler G., Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 1999, 16:3771-3777.
24. Pautz A., Art J., Hahn S., Nowag S., Voss C., Kleinert H. Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 2010, 23:75-93.
25. Robertson K.R., Su Z., Margolis D.M., Krambrink A., Havlir D.V., Evans S., Skiest D.J. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010, 74:1260-1266.
26. Robertson K., Liner J., Meeker R.B. Antiretroviral neurotoxicity. J. Neurovirol. 2012, 18:388-399.
27. Ryo A., Suzuki Y., Arai M., Kondoh N., Wakatsuki T., Hada A., Shuda M., Tanaka K., Sato C., Yamamoto M., Yamamoto N. Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res. Hum. Retrovir. 2000, 16:995-1005.
28. Saha R.N., Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid. Redox Signal. 2006, 8:929-947.
29. Smurzynski M., Wu K., Letendre S., Robertson K., Bosch R.J., Clifford D.B., Evans S., Collier A.C., Taylor M., Ellis R. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25:357-365.
30. Valcour V., Shikuma C., Shiramizu B., Watters M., Poff P., Selnes O., Holck P., Grove J., Sacktor N. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 2004, 63:822-827.
31. Valcour V., Sithinamsuwan P., Letendre S., Ances B. Pathogenesis of HIV in the central nervous system. Curr. HIV/AIDS Rep. 2011, 8:54-61.
32. Yilmaz A., Price R.W., Gisslén M. Antiretroviral drug treatment of CNS HIV-1 infection. J. Antimicrob. Chemother. 2012, 67:299-311.
33. Zea A.H., Culotta K.S., Ali J., Mason C., Park H.J., Zabaleta J., Garcia L.F., Ochoa A.C. Decreased expression of CD3zeta and nuclear transcription factor kappa B in patients with pulmonary tuberculosis: potential mechanisms and reversibility with treatment. J. Infect. Dis. 2006, 2006(194):1385-1393.
34. Zharikov S., Krotova K., Hu H., Baylis C., Johnson R.J., Block E.R., Patel J. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am. J. Physiol. Cell Physiol. 2008, 295:C1183-C1190.